Cynergy treats vascular and pigmented lesions more effectively than conventional, single-wavelength platforms. With both a high-powered 585 nm pulsed-dye laser and a 1064 nm Nd:YAG laser, proprietary MultiPlex technology enables the sequential emission of two wavelengths from one delivery system for optimised clinical effectiveness.
Sequential emission means that Cynergy’s sub-purpuric, pulsed-dye laser fires milliseconds before the Nd:YAG laser. This first pulse converts oxy-hemoglobin to methemoglobin, which increases the absorption coefficient for the Nd:YAG wavelength by 300–500%.2,3
Next, the Nd:YAG laser fires and is more effectively absorbed by the converted target, enabling reduced Nd:YAG fluence for enhanced patient comfort. Since greater penetration depth is achieved, outcome results are also optimised.
By emitting dual wavelengths, Cynergy provides effective results in less time than single-wavelength systems. For your patients, that means greater comfort and satisfaction. For you, that means greater patient throughput.
1Geronemus R J Dermatol Surg Oncol. 1993;19:303–310.
2Barton JK, et al. Optical and magnetic resonance changes in photothermally coagulating blood. Proceedings of SPIE 2002; 4609:10-19.
3Kuenstner JT, Norris KH. Spectrophotometry of human hemoglobin in the near infrared region from 1000 to 2500 nm. Near Infrared Spectrosc 1994;2:59-65.
Cynergy is the first system to combine a long pulse pulse-dye-laser and a high powered Nd:YAG into one system. These wavelengths were chosen for their absorption characteristics and depth of penetration. Both wavelengths are well absorbed by blood.
Both wavelengths are also absorbed by melanin. The wavelengths are synergistic in their depth of penetration criteria, the PDL has a more shallow depth of penetration while the ND:YAG penetrates deeper.
MultiPlex is the ability to sequentially fire different laser wavelengths through the same handpiece, with precise timing, to improve the outcome of treatment compared to single wavelength treatment. MultiPlex refers to Cynergy’s combination of PDL followed by
YAG, with short, medium, long and extended delays between wavelengths.
MultiPlex has been shown to provide 75% single-treatment clearance in 75% of subjects when treating facial telangiectasia, with little or no purpura. MultiPlex improves treatment of leg veins as well. MultiPlex has also been shown to improve outcomes for
those with recalcitrant and resistant vascular birthmarks, and to allow treatment of lesions previously requiring surgery.
MultiPlex is the preferred method of treatment for discrete telangiectatic vessels from 0.2 to 1.2 mm in diameter, on the face and legs. It also provides additional treatment options for resistant or recalcitrant vascular birthmarks.
PDL energy is very well absorbed by blood (about 50x better than Nd:YAG), hence very little energy (typically less than 10 j/cm2) is required to heat blood sufficiently to cause conversion to Methemoglobin and/or thrombus (PDL products). Thus there is little
background heating of tissue and less risk of thermal injury. Both Methemoglobin and thrombus provide favourable absorption characteristics for Nd:YAG (~3-5x better then normal blood), thus modest Nd:YAG fluence is required to provide effective treatment.
Because less Nd:YAG energy is used, there is a lower risk of side effects than Nd:YAG alone. The Nd:YAG absorption characteristics of Methemoglobin and thrombus are still much lower (~10x) than PDL, thus depth of penetration is not sacrificed.
General perfusion causes Methemoglobin and thrombus to flow deeper into the dermal tissue between the penetration depths of PDL & Nd:YAG wavelengths. This allows the Nd:YAG energy to interact at depth, with PDL exposure products that were created more
superficially. Detailed studies have shown that even when a vessel appears to be clotted, there is typically some residual flow, allowing propagation of PDL products.
Yes, the PDL does introduce residual heat into the field of Nd:YAG treatment. Without efficient epidermal cooling, this can lead to epidermal injury.
Immediate vessel disappearance during laser treatment is a sign of vasospasm. Vasospasm occurs when a vessel is damaged, or irritated, but not necessarily destroyed. In the majority of cases, a vessel that displays vasospasm has been under treated, and will
return within days or weeks. Intravascular coagulation (darkening of the vessel itself, which cannot be blanched) is the preferred endpoint for treatment of telangiectasia, suggesting effective damage to the vessel wall. Intravascular coagulation generally
resolves within 1-3 weeks.
As a recognised industry leader, Cynosure’s Cynergy technology is strongly supported by clinical research.